Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Gynecology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 91 articles: HTML format

Single Articles

May 2023
1. PESOLA F, Rebolj M, Sasieni P
   Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.
   Int J Cancer. 2023;152:2061-2068.
   PubMed     Abstract available
   
   
   March 2023
2. QIN Z, Li J, Tam B, Sinha S, et al
   Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
   Int J Cancer. 2023;152:1159-1173.
   PubMed     Abstract available
   
   
   
3. WEVER BMM, van den Helder R, van Splunter AP, van Gent MDJM, et al
   DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples, and cervical scrapes.
   Int J Cancer. 2023 Mar 13. doi: 10.1002/ijc.34504.
   PubMed     Abstract available
   
   
   
4. SILVA R, Glennon K, Metoudi M, Moran B, et al
   Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
   Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34496.
   PubMed     Abstract available
   
   
   
5. SIEVANEN T, Korhonen TM, Jokela T, Ahtiainen M, et al
   Systemic circulating microRNA landscape in Lynch syndrome.
   Int J Cancer. 2023;152:932-944.
   PubMed     Abstract available
   
   
   February 2023
6. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
   Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
   Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
   PubMed     Abstract available
   
   
   January 2023
7. CASAS-AROZAMENA C, Moiola CP, Vilar A, Bouso M, et al
   Non-Invasive Detection of Microsatellite Instability in patients with Endometrial Cancer.
   Int J Cancer. 2023 Jan 17. doi: 10.1002/ijc.34435.
   PubMed     Abstract available
   
   
   
8. HUANG RY, Huang KJ, Chen KC, Hsiao SM, et al
   Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
   Int J Cancer. 2023 Jan 11. doi: 10.1002/ijc.34428.
   PubMed     Abstract available
   
   
   December 2022
9. VELLE A, Pesenti C, Grassi T, Beltrame L, et al
   A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers.
   Int J Cancer. 2022 Dec 21. doi: 10.1002/ijc.34408.
   PubMed     Abstract available
   
   
   
10. BARRETT JE, Jones A, Evans I, Herzog C, et al
    The WID-EC test for the detection and risk prediction of endometrial cancer.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34406.
    PubMed     Abstract available
    
    
    
11. CABASAG CJ, Arnold M, Rutherford M, Ferlay J, et al
    Shifting incidence and survival of epithelial ovarian cancer (1995-2014): a SurvMark-2 study.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34403.
    PubMed     Abstract available
    
    
    
12. SAKAKIBARA A, Nakayama T, Uchida H, Odagiri Y, et al
    Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34391.
    PubMed     Abstract available
    
    
    
13. ROBERTS JM, Machalek DA, Butler BC, Crescini J, et al
    Older women testing positive for HPV 16/18 on cervical screening and risk of high-grade cervical abnormality.
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34393.
    PubMed     Abstract available
    
    
    November 2022
14. BAENA A, Mesher D, Salgado Y, Martinez S, et al
    Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study.
    Int J Cancer. 2022 Nov 30. doi: 10.1002/ijc.34384.
    PubMed     Abstract available
    
    
    
15. WANG Z, Phillips LS, Rohan TE, Ho GY, et al
    Diabetes, Metformin Use, and Risk of Non-Hodgkin's Lymphoma in Postmenopausal Women: A Prospective Cohort Analysis in the Women's Health Initiative.
    Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34376.
    PubMed     Abstract available
    
    
    
16. GOTTSCHLICH A, Payne BA, Trawin J, Albert A, et al
    Experiences with thermal ablation for cervical pre-cancer treatment after self-collection HPV-based screening in the ASPIRE Mayuge randomized trial.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34369.
    PubMed     Abstract available
    
    
    
17. KOBAYASHI R, Kawabata-Iwakawa R, Sugiyama M, Oyama T, et al
    Multiplexed genome editing by in vivo electroporation of Cas9 ribonucleoproteins effectively induces endometrial carcinoma in mice.
    Int J Cancer. 2022 Nov 15. doi: 10.1002/ijc.34342.
    PubMed     Abstract available
    
    
    
18. HANNIBAL CG, Baandrup L, Hertzum-Larsen R, Vang R, et al
    Risk of non-ovarian cancer in a nationwide-based study of nearly 5,000 women with borderline ovarian tumors in Denmark.
    Int J Cancer. 2022 Nov 10. doi: 10.1002/ijc.34354.
    PubMed     Abstract available
    
    
    
19. PARKER VL, Winter MC, Tidy JA, Hancock BW, et al
    PREDICT-GTN 1: Can we improve the FIGO scoring system in Gestational Trophoblastic Neoplasia?
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34352.
    PubMed     Abstract available
    
    
    October 2022
20. GIZAW M, Parkin DM, Stoter O, Korir A, et al
    Trends in the Incidence of Ovarian Cancer in sub-Saharan Africa.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34335.
    PubMed     Abstract available
    
    
    
21. SIVARS L, Palsdottir K, Crona Guterstam Y, Falconer H, et al
    The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34333.
    PubMed     Abstract available
    
    
    
22. VAN DER MEER R, Bakkers C, van Erning FN, Simkens LHJ, et al
    A propensity score matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34325.
    PubMed     Abstract available
    
    
    
23. RING LL, Munk C, Galanakis M, Tota JE, et al
    Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019 - population impact of multi-cohort vaccination against human papillomavirus infection.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34328.
    PubMed     Abstract available
    
    
    
24. YAO J, Takenaga K, Koshikawa N, Kida Y, et al
    Anticancer effect of a pyrrole-imidazole polyamide-triphenylphosphonium conjugate selectively targeting a common mitochondrial DNA cancer risk variant in cervical cancer cells.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34319.
    PubMed     Abstract available
    
    
    
25. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed     Abstract available
    
    
    
26. RAKISLOVA N, Carreras-Dieguez N, Manzotti C, Saude O, et al
    Differential etiopathogenic features of vulvar squamous cell carcinomas in sub-Saharan Africa and Europe.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34314.
    PubMed     Abstract available
    
    
    
27. SAUVAGET C, Bazikamwe S, Lucas E, Ndayikengurukiye A, et al
    Evaluation of effectiveness, acceptability and safety of thermal ablation in the treatment of cervical neoplasia in Burundi.
    Int J Cancer. 2022;151:1120-1126.
    PubMed     Abstract available
    
    
    September 2022
28. ADEBAMOWO SN, Befano B, Cheung LC, Rodriguez AC, et al
    Different human papillomavirus types share early natural history transitions in immunocompetent women.
    Int J Cancer. 2022;151:920-929.
    PubMed     Abstract available
    
    
    
29. ZHONG GC, Zhu Q, Cai D, Hu JJ, et al
    Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34290.
    PubMed     Abstract available
    
    
    
30. KAHESA C, Thomsen LT, Linde DS, Mchome B, et al
    Comparison of human papillomavirus (HPV)-based cervical cancer screening strategies in Tanzania among women with and without HIV.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34283.
    PubMed     Abstract available
    
    
    
31. LEHTINEN M, Pimenoff VN, Nedjai B, Louvanto K, et al
    Assessing the risk of cervical neoplasia in the post-HPV vaccination era.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34286.
    PubMed     Abstract available
    
    
    
32. SCHREIBERHUBER L, Herzog C, Vavourakis CD, Redl E, et al
    The WID(TM) -qEC test - performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers.
    Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34275.
    PubMed     Abstract available
    
    
    August 2022
33. FRENSEMEIER K, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F, et al
    Dickkopf-1 expression is repressed by oncogenic human papillomaviruses (HPVs) and regulates the Cisplatin sensitivity of HPV-positive cancer cells in a JNK-dependent manner.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34250.
    PubMed     Abstract available
    
    
    
34. LI Y, Chen R, Yuan M, Wang D, et al
    One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34241.
    PubMed     Abstract available
    
    
    
35. NORMAN I, Yilmaz E, Hjerpe A, Hortlund M, et al
    Atypical glandular cells and development of cervical cancer: Population-based cohort study.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34242.
    PubMed     Abstract available
    
    
    
36. SENGAYI-MUCHENGETI M, Singh E, Chen WC, Bradshaw D, et al
    Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995-2016).
    Int J Cancer. 2022 Aug 4. doi: 10.1002/ijc.34236.
    PubMed     Abstract available
    
    
    July 2022
37. GARGANO JW, McClung N, Lewis RM, Park IU, et al
    HPV type-specific trends in cervical precancers in the United States, 2008-2016.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34231.
    PubMed     Abstract available
    
    
    
38. BHATT A, Bhandoria G, Kepenekian V, Bakrin N, et al
    Comments on ' Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial'.
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34220.
    PubMed    
    
    
    
39. KOOLE SN, Schouten PC, van Driel WJ, Sonke GS, et al
    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial".
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34219.
    PubMed    
    
    
    
40. JOSHI S, Muwonge R, Kulkarni V, Mandolkar M, et al
    Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
    Int J Cancer. 2022 Jul 19. doi: 10.1002/ijc.34221.
    PubMed     Abstract available
    
    
    June 2022
41. YOON M, Lee HK, Park EY, Kim JH, et al
    Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study.
    Int J Cancer. 2022 Jun 25. doi: 10.1002/ijc.34190.
    PubMed     Abstract available
    
    
    
42. HUSBY A, Wohlfahrt J, Melbye M
    Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study.
    Int J Cancer. 2022 Jun 24. doi: 10.1002/ijc.34192.
    PubMed     Abstract available
    
    
    
43. CAO H, Gong Y, Wang Y
    The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta-analysis and trial sequential analysis.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34179.
    PubMed     Abstract available
    
    
    
44. BAANDRUP L, Galanakis M, Hannibal CG, Dehlendorff C, et al
    Long-term survival of non-localized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis - the Extreme study.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34171.
    PubMed     Abstract available
    
    
    
45. AUVINEN E, Nieminen P, Pellinen J, Dillner J, et al
    HPV self-sampling with mRNA testing benefits routine screening.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34170.
    PubMed     Abstract available
    
    
    
46. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
    The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
    PubMed     Abstract available
    
    
    
47. TODISCO E, Gigli F, Ronchini C, Amato V, et al
    Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.
    Int J Cancer. 2022 Jun 13. doi: 10.1002/ijc.34162.
    PubMed     Abstract available
    
    
    
48. SA JK, Kim J, Kang S, Kim SW, et al
    Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34150.
    PubMed     Abstract available
    
    
    
49. HAMPL M, Hesselink AT, Meijer CJLM, Denecke A, et al
    Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34153.
    PubMed     Abstract available
    
    
    
50. DESAI KT, Adepiti CA, Schiffman M, Egemen D, et al
    Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34151.
    PubMed     Abstract available
    
    
    May 2022
51. HARRIS HR, Guertin KA, Camacho TF, Johnson CE, et al
    Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.
    Int J Cancer. 2022 May 28. doi: 10.1002/ijc.34141.
    PubMed     Abstract available
    
    
    
52. KOOLE SN, Schouten PC, Hauke J, Kluin RJC, et al
    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.
    Int J Cancer. 2022 May 18. doi: 10.1002/ijc.34124.
    PubMed     Abstract available
    
    
    
53. GIORGI ROSSI P, Ronco G, Mancuso P, Carozzi F, et al
    Performance of HPV E6/E7 mRNA Assay as Primary Screening Test. Results from the NTCC2 Trial.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34120.
    PubMed     Abstract available
    
    
    
54. JAIN S, Nadeem N, Ulfenborg B, Makela M, et al
    Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
    Int J Cancer. 2022 May 9. doi: 10.1002/ijc.34111.
    PubMed     Abstract available
    
    
    
55. BURGER EA, Laprise JF, Sy S, Regan MC, et al
    Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.
    Int J Cancer. 2022 May 5. doi: 10.1002/ijc.34054.
    PubMed     Abstract available
    
    
    
56. HURTADO-SALGADO E, Cardenas-Cardenas L, Salmeron J, Luna-Gordillo R, et al
    Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level.
    Int J Cancer. 2022;150:1422-1430.
    PubMed     Abstract available
    
    
    April 2022
57. ADCOCK R, Nedjai B, Lorincz A, Scibior-Bentkowska D, et al
    DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Int J Cancer. 2022 Apr 27. doi: 10.1002/ijc.34050.
    PubMed     Abstract available
    
    
    
58. GOTTSCHLICH A, Gondara L, Smith LW, Cook D, et al
    HPV-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV FOr CervicAL Cancer (HPV FOCAL) trial.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34039.
    PubMed     Abstract available
    
    
    
59. ZHANG L, Zhao X, Hu S, Chen S, et al
    Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.
    PubMed     Abstract available
    
    
    
60. ROMANI C, Capoferri D, Reijnen C, Lonardi S, et al
    L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34035.
    PubMed     Abstract available
    
    
    
61. STANCZUK GA, Currie H, Forson W, Baxter G, et al
    Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study.
    Int J Cancer. 2022;150:1350-1356.
    PubMed     Abstract available
    
    
    
62. SAHASRABUDDHE VV, Castle PE, Schiffman M, Wentzensen N, et al
    Reply to: Comments on 'Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening'.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34013.
    PubMed    
    
    
    
63. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    PubMed     Abstract available
    
    
    
64. BRENTNALL AR, Rebolj M
    Comments on: "Meta-analysis of agreement/concordance statistics in studies comparing self-versus clinician-collected samples for HPV testing in cervical cancer screening".
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34014.
    PubMed    
    
    
    March 2022
65. ZHAO Y, Gao YT, Zhang X, Rockwood AL, et al
    Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never-smoking women.
    Int J Cancer. 2022 Mar 26. doi: 10.1002/ijc.34005.
    PubMed     Abstract available
    
    
    
66. CABASAG CJ, Fagan PJ, Ferlay J, Vignat J, et al
    Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020.
    Int J Cancer. 2022 Mar 23. doi: 10.1002/ijc.34002.
    PubMed     Abstract available
    
    
    February 2022
67. LUPIA M, Melocchi V, Bizzaro F, Lo Riso P, et al
    Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
    Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33983.
    PubMed     Abstract available
    
    
    
68. ARBYN M, Castle PE, Schiffman M, Wentzensen N, et al
    Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33967.
    PubMed     Abstract available
    
    
    January 2022
69. YAN X, Zhao W, Wei J, Yao Y, et al
    A serum lipidomics study for the identification of specific biomarkers for endometrial polyps to distinguish them from endometrial cancer or hyperplasia.
    Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33943.
    PubMed     Abstract available
    
    
    
70. MAILLIEZ A, Pigny P, Bogart E, Keller L, et al
    Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
    Int J Cancer. 2022 Jan 17. doi: 10.1002/ijc.33933.
    PubMed     Abstract available
    
    
    
71. VAN DER WATT PJ, Okpara MO, Wishart A, Parker MI, et al
    Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkers.
    Int J Cancer. 2022;150:347-361.
    PubMed     Abstract available
    
    
    
72. YAGI A, Ueda Y, Ikeda S, Miyoshi A, et al
    Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis.
    Int J Cancer. 2022;150:232-242.
    PubMed     Abstract available
    
    
    December 2021
73. PARK B
    Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk.
    Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33906.
    PubMed     Abstract available
    
    
    
74. HERMENS M, van Altena AM, van der Aa M, Bulten J, et al
    Endometrial cancer prognosis in women with endometriosis and adenomyosis. A retrospective nationwide cohort study of 40,840 women.
    Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33907.
    PubMed     Abstract available
    
    
    
75. HORTLUND M, Muhr LSA, Lagheden C, Hjerpe A, et al
    Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
    Int J Cancer. 2021;149:2083-2090.
    PubMed     Abstract available
    
    
    
76. REBOLJ M, Mathews CS, Pesola F, Castanon A, et al
    Acceleration of Cervical Cancer Diagnosis with Human Papillomavirus Testing Below Age 30: Observational Study.
    Int J Cancer. 2021 Dec 12. doi: 10.1002/ijc.33900.
    PubMed     Abstract available
    
    
    
77. PERSSON MS, Yin W, Doring N, Risnes K, et al
    Gestational age and cancer risk up to young adulthood in Swedish population born 1974-2013: a population-based cohort study.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33886.
    PubMed     Abstract available
    
    
    November 2021
78. DESAI KT, Befano B, Xue Z, Kelly H, et al
    The development of "Automated Visual Evaluation" for cervical cancer screening: The promise and challenges in adapting deep-learning for clinical testing.
    Int J Cancer. 2021 Nov 20. doi: 10.1002/ijc.33879.
    PubMed     Abstract available
    
    
    
79. KIM DS, Ahn HS, Kim HJ
    Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database.
    Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33869.
    PubMed     Abstract available
    
    
    
80. BERGHUIS AY, Pijnenborg JFA, Boltje TJ, Pijnenborg JMA, et al
    Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33866.
    PubMed     Abstract available
    
    
    
81. SPENCER JC, Campos NG, Burger EA, Sy S, et al
    Potential Effectiveness of a Therapeutic HPV Intervention Campaign in Uganda.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33867.
    PubMed     Abstract available
    
    
    October 2021
82. ISLAM S, Dutta P, Sahay O, Gopalakrishnan K, et al
    Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33854.
    PubMed     Abstract available
    
    
    
83. RAVEGNINI G, Gorini F, De Crescenzo E, De Leo A, et al
    Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33857.
    PubMed     Abstract available
    
    
    
84. GUSTINUCCI D, Benevolo M, Cesarini E, Mancuso P, et al
    Accuracy of Different Triage Strategies for HPV Positivity in an Italian Screening Population.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33858.
    PubMed     Abstract available
    
    
    
85. HARPER DM, Rozek LS
    Cervical cancer prevention becomes more efficient.
    Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33851.
    PubMed    
    
    
    
86. PEDERSEN K, Portnoy A, Sy S, Hansen BT, et al
    Switching clinic-based cervical cancer screening programs to HPV self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Int J Cancer. 2021 Oct 18. doi: 10.1002/ijc.33850.
    PubMed     Abstract available
    
    
    
87. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
    Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
    PubMed     Abstract available
    
    
    
88. IBRAHIM KHALIL A, Mpunga T, Wei F, Baussano I, et al
    Age-specific burden of cervical cancer associated with HIV: a global analysis with a focus on sub-Saharan Africa.
    Int J Cancer. 2021 Oct 9. doi: 10.1002/ijc.33841.
    PubMed     Abstract available
    
    
    September 2021
89. BANILA C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, et al
    Clinical performance of methylation as a biomarker for cervical carcinoma-in-situ and cancer diagnosis: a worldwide study.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33815.
    PubMed     Abstract available
    
    
    
90. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
    Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33820.
    PubMed     Abstract available
    
    
    
91. WRIGHT TC JR, Stoler MH, Ranger-Moore J, Fang Q, et al
    Clinical Validation of p16/Ki-67 Dual-Stained Cytology Triage of HPV-Positive Women - Results from the IMPACT Trial.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33812.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: